



PHARMACY POLICY STATEMENT Indiana Medicaid

DRUG NAME	Breyanzi (lisocabtagene maraleucel)
BILLING CODE	Q2054
BENEFIT TYPE	Carved out to FFS (fee-for-service) benefit
SITE OF SERVICE ALLOWED	N/A
COVERAGE REQUIREMENTS	Please see Indiana Fee-For-Service website

Tecartus (brexucabtagene autoleucel) is a product that is carved out from managed care benefits and is included in the Indiana Medicaid Fee-For-Service (FFS) program. Requests for coverage of this product must be submitted directly to OptumRx for review.

DATE	ACTION/DESCRIPTION
04/22/2021	Statement regarding the carved-out status created.

Effective date: 10/01/2021

Revised date: 04/22/2021